ALNAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-06-03), Allena Pharmaceuticals's Intrinsic Value: Projected FCF is $0.00. The stock price of Allena Pharmaceuticals is $1.0E-6. Therefore, Allena Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Allena Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
The historical data trend for Allena Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Allena Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | -3.16 | -2.94 |
For the Biotechnology subindustry, Allena Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Allena Pharmaceuticals's Free Cash Flow(6 year avg) = $-31.38.
Allena Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Jun22) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | -31.38096 | + | 3.741 | * | 0.8) | / | 100.624 | |
= | -2.94 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals (OTCPK:ALNAQ) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Allena Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 1.0E-6 | / | -2.939308441514 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Allena Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Louis Md Brenner | officer: See Remarks | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140 |
Mark J. Fitzpatrick | director | 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Richard D Katz | officer: Chief Financial Officer | 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703 |
Edward Wholihan | officer: Chief Financial Officer | C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Allene M. Diaz | director | C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Bessemer Venture Partners Vii L.p. | 10 percent owner | C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538 |
Hbm Biocapital Ii Lp | 10 percent owner | 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH |
James N Topper | director, 10 percent owner | 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301 |
Fhm Vi, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Robert I Tepper | director, 10 percent owner | 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Robert Alexander | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Alexey L Margolin | director, officer: Chief Executive Officer | C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired Marketwired • 09-09-2021
By PRNewswire PRNewswire • 06-01-2022
By Marketwired Marketwired • 07-07-2021
By PurpleRose PurpleRose • 07-19-2022
By PRNewswire PRNewswire • 07-28-2021
By Don Li2 Don Li2 • 11-03-2021
By PRNewswire PRNewswire • 07-01-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired Marketwired • 08-03-2021
By Marketwired Marketwired • 08-10-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.